CN1518558B - 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 - Google Patents

肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 Download PDF

Info

Publication number
CN1518558B
CN1518558B CN018225993A CN01822599A CN1518558B CN 1518558 B CN1518558 B CN 1518558B CN 018225993 A CN018225993 A CN 018225993A CN 01822599 A CN01822599 A CN 01822599A CN 1518558 B CN1518558 B CN 1518558B
Authority
CN
China
Prior art keywords
peptide
pharmaceutical composition
pro
protein
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018225993A
Other languages
English (en)
Chinese (zh)
Other versions
CN1518558A (zh
Inventor
P·佩策尔保尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Publication of CN1518558A publication Critical patent/CN1518558A/zh
Application granted granted Critical
Publication of CN1518558B publication Critical patent/CN1518558B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN018225993A 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途 Expired - Fee Related CN1518558B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
ATA2063/2000 2000-12-12
PCT/AT2001/000387 WO2002048180A2 (de) 2000-12-12 2001-12-07 Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910163553A Division CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Publications (2)

Publication Number Publication Date
CN1518558A CN1518558A (zh) 2004-08-04
CN1518558B true CN1518558B (zh) 2010-06-16

Family

ID=3689750

Family Applications (2)

Application Number Title Priority Date Filing Date
CN018225993A Expired - Fee Related CN1518558B (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
CN200910163553A Pending CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910163553A Pending CN101676299A (zh) 2000-12-12 2001-12-07 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途

Country Status (30)

Country Link
US (4) US7271144B2 (https=)
EP (2) EP1586586B1 (https=)
JP (1) JP4181874B2 (https=)
KR (1) KR100864069B1 (https=)
CN (2) CN1518558B (https=)
AT (2) ATE329614T1 (https=)
AU (1) AU2002221316A1 (https=)
BG (1) BG107891A (https=)
BR (1) BR0116122A (https=)
CA (1) CA2430972C (https=)
CY (2) CY1106108T1 (https=)
CZ (1) CZ20031630A3 (https=)
DE (2) DE50110182D1 (https=)
DK (2) DK1341819T3 (https=)
EA (1) EA005576B1 (https=)
EE (1) EE200300283A (https=)
ES (2) ES2266093T3 (https=)
HR (1) HRP20030564A2 (https=)
HU (1) HUP0401536A3 (https=)
IL (2) IL156360A0 (https=)
MX (1) MXPA03005218A (https=)
NO (1) NO330767B1 (https=)
NZ (1) NZ550619A (https=)
PL (2) PL209752B1 (https=)
PT (2) PT1341819E (https=)
SI (2) SI1586586T1 (https=)
SK (1) SK7062003A3 (https=)
WO (1) WO2002048180A2 (https=)
YU (1) YU53803A (https=)
ZA (1) ZA200304545B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221316A1 (en) 2000-12-12 2002-06-24 Fibrex Medical Research & Development Gmbh Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
CA2544676A1 (en) * 2004-06-25 2006-01-05 Fibrex Medical Research & Development Gesmbh Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
US20080004220A1 (en) * 2006-02-23 2008-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987062B1 (en) * 2006-02-23 2011-06-22 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
FR2900657B1 (fr) 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
US8722623B2 (en) 2007-09-17 2014-05-13 University Of Maryland, Baltimore Compositions and methods utilizing fibrin beta chain fragments
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2017210539A1 (en) 2016-06-02 2017-12-07 University Of Maryland, Baltimore Compositions for inhibiting fibrin-vldl receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
AU2002221316A1 (en) * 2000-12-12 2002-06-24 Fibrex Medical Research & Development Gmbh Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
US7201763B2 (en) 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SKOGEN W F等.Fibrinogen-Derived Petide Bβ1-42 Isa Multidomained Neutrophil Chemoattractant.Blood71 5.1988,摘要、图4以及第1478页右栏第12-13行和最后一段.
SKOGEN W F等.Fibrinogen-Derived Petide Bβ1-42 Isa Multidomained Neutrophil Chemoattractant.Blood71 5.1988,摘要、图4以及第1478页右栏第12-13行和最后一段. *

Also Published As

Publication number Publication date
HUP0401536A2 (hu) 2004-11-29
CY1106108T1 (el) 2011-06-08
SI1341819T1 (sl) 2006-10-31
BG107891A (bg) 2004-08-31
CY1109107T1 (el) 2014-07-02
NO330767B1 (no) 2011-07-11
CA2430972A1 (en) 2002-06-20
HRP20030564A2 (en) 2005-06-30
WO2002048180A3 (de) 2003-01-30
EE200300283A (et) 2003-10-15
EP1586586B1 (de) 2009-03-11
SK7062003A3 (en) 2003-11-04
US20040192596A1 (en) 2004-09-30
NZ550619A (en) 2008-06-30
IL156360A0 (en) 2004-01-04
US20090088384A1 (en) 2009-04-02
JP4181874B2 (ja) 2008-11-19
EA200300678A1 (ru) 2003-10-30
IL156360A (en) 2012-12-31
JP2004527469A (ja) 2004-09-09
EP1586586A2 (de) 2005-10-19
US20070037749A1 (en) 2007-02-15
US7811985B2 (en) 2010-10-12
ES2323963T3 (es) 2009-07-28
WO2002048180A2 (de) 2002-06-20
US7494973B2 (en) 2009-02-24
EA005576B1 (ru) 2005-04-28
PL209419B1 (pl) 2011-08-31
US20090137464A1 (en) 2009-05-28
YU53803A (sh) 2006-03-03
NO20032656D0 (no) 2003-06-12
DK1586586T3 (da) 2009-06-29
DE50114771D1 (de) 2009-04-23
PT1586586E (pt) 2010-05-28
US7271144B2 (en) 2007-09-18
KR20030060988A (ko) 2003-07-16
CZ20031630A3 (cs) 2003-10-15
PL362924A1 (en) 2004-11-02
EP1341819A2 (de) 2003-09-10
ES2266093T3 (es) 2007-03-01
MXPA03005218A (es) 2004-12-03
PL209752B1 (pl) 2011-10-31
EP1341819B1 (de) 2006-06-14
ZA200304545B (en) 2004-09-13
NO20032656L (no) 2003-06-12
SI1586586T1 (sl) 2009-08-31
KR100864069B1 (ko) 2008-10-16
DK1341819T3 (da) 2006-10-16
ATE425184T1 (de) 2009-03-15
AU2002221316A1 (en) 2002-06-24
HK1084400A1 (zh) 2006-07-28
DE50110182D1 (de) 2006-07-27
BR0116122A (pt) 2003-10-14
PT1341819E (pt) 2006-10-31
HUP0401536A3 (en) 2008-09-29
CN1518558A (zh) 2004-08-04
CN101676299A (zh) 2010-03-24
CA2430972C (en) 2014-08-05
ATE329614T1 (de) 2006-07-15
EP1586586A3 (de) 2006-03-29
US8067373B2 (en) 2011-11-29

Similar Documents

Publication Publication Date Title
CN1518558B (zh) 肽和/或蛋白质及其用于制备治疗性和/或预防性药物组合物的用途
AU648520B2 (en) Methods and compositions for healing bone
Shebuski et al. Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration
JP2004527469A6 (ja) ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
JPH03118331A (ja) 環状フイブリノーゲンレセプター拮抗薬
JP3930050B2 (ja) 平滑筋細胞増殖抑制能を有する新規ペプチド
JP4668612B2 (ja) トロンビンペプチド誘導体ダイマー
JP4338516B2 (ja) 血管新生剤
JPH06234653A (ja) 歯周組織再生促進剤および材料
HK1140212A (en) Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical
HK1084400B (en) Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
JPH0641193A (ja) ペプチド誘導体およびその用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20161207